Molecular characterization of the salivary adenoid cystic carcinoma immune landscape by anatomic subsites.
Adenoid cystic carcinoma (AdCC)
Salivary gland cancer (SGC)
Tumor biology
Tumor immune microenvironment (TIME)
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 Jul 2024
09 Jul 2024
Historique:
received:
10
04
2024
accepted:
02
07
2024
medline:
10
7
2024
pubmed:
10
7
2024
entrez:
9
7
2024
Statut:
epublish
Résumé
Adenoid cystic carcinoma (AdCC) is a slow-growing salivary gland malignancy that relapses frequently. AdCCs of the submandibular gland exhibit unique differences in prognosis and treatment response to adjuvant radiotherapy compared to other sites, yet the role of tumor anatomic subsite on gene expression and tumor immune microenvironment (TIME) composition remains unclear. We used 87 samples, including 48 samples (27 AdCC and 21 normal salivary gland tissue samples) from 4 publicly available AdCC RNA sequencing datasets, a validation set of 33 minor gland AdCCs, and 39 samples from an in-house cohort (30 AdCC and 9 normal salivary gland samples). RNA sequencing data were used for single sample gene set enrichment analysis and TIME deconvolution. Quantitative PCR and multiplex immunofluorescence were performed on the in-house cohort. Wilcoxon rank-sum, nonparametric equality-of-medians tests and linear regression models were used to evaluate tumor subsite differences. AdCCs of different anatomic subsites including parotid, submandibular, sublingual, and minor salivary glands differed with respect to expression of several key tumorigenic pathways. Among the three major salivary glands, the reactive oxygen species (ROS)/nuclear factor erythroid 2-related factor 2 (NRF2) pathway signature was significantly underexpressed in AdCC of submandibular compared to parotid and sublingual glands while this association was not observed among normal glands. Additionally, the NRF2 pathway, whose expression was associated with favorable overall survival, was overexpressed in AdCCs of parotid gland compared to minor and submandibular glands. The TIME deconvolution identified differences in CD4
Identifiants
pubmed: 38982149
doi: 10.1038/s41598-024-66709-3
pii: 10.1038/s41598-024-66709-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15821Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR)
ID : R01DE30123
Informations de copyright
© 2024. The Author(s).
Références
El-Naggar, A. K. C. J., Grandis, J. R., Takata, T. & Slootweg, P. J. WHO Classification of Head and Neck Tumours 4th edn. (IARC Press, 2016).
Eveson, D. R., Henley, J. D. & Simpson, R. H. W. Diagnostic Surgical Pathology of the Head and Neck E-Book (Elsevier Health Sciences, 2009).
NCCN. Head and neck cancers, version 1.2019. In National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Head and Neck Cancers (version 2.2019). (2019) https://www.ncbi.nlm.nih.gov/pubmed/23946171 .
Laurie, S. A. et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: A systematic review. Lancet Oncol. 12, 815–824 (2011).
pubmed: 21147032
doi: 10.1016/S1470-2045(10)70245-X
Sogono, P. G., Mejia, M. B. A. & Agas, R. A. F. Addition of concurrent chemotherapy to adjuvant radiotherapy versus radiotherapy alone for resected salivary gland cancers: A systematic review and meta-analysis. J. Clin. Oncol. 35, e17563 (2017).
doi: 10.1200/JCO.2017.35.15_suppl.e17563
Miller, L. E. et al. A contemporary review of molecular therapeutic targets for adenoid cystic carcinoma. Cancers 14, 992 (2022).
pubmed: 35205740
pmcid: 8869877
doi: 10.3390/cancers14040992
Mitani, Y. et al. Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: Association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clin. Cancer Res. 17, 7003–7014 (2011).
pubmed: 21976542
pmcid: 3225955
doi: 10.1158/1078-0432.CCR-11-1870
Mitani, Y. et al. Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations. Clin. Cancer Res. 22, 725–733 (2016).
pubmed: 26631609
doi: 10.1158/1078-0432.CCR-15-2867-T
Brayer, K. J. et al. Recurrent fusions in MYB and MYBL1 define a common, transcription factor-driven oncogenic pathway in salivary gland adenoid cystic carcinoma. Cancer Discov. 6, 176–187 (2016).
pubmed: 26631070
doi: 10.1158/2159-8290.CD-15-0859
Frerich, C. A. et al. Transcriptomes define distinct subgroups of salivary gland adenoid cystic carcinoma with different driver mutations and outcomes. Oncotarget 9, 7341–7358 (2018).
pubmed: 29484115
doi: 10.18632/oncotarget.23641
Drier, Y. et al. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nat. Genet. 48, 265–272 (2016).
pubmed: 26829750
pmcid: 4767593
doi: 10.1038/ng.3502
Togashi, Y. et al. MYB and MYBL1 in adenoid cystic carcinoma: Diversity in the mode of genomic rearrangement and transcripts. Mod. Pathol. 31, 934–946 (2018).
pubmed: 29410490
doi: 10.1038/s41379-018-0008-8
van Weert, S. et al. Histopathological grading of adenoid cystic carcinoma of the head and neck: Analysis of currently used grading systems and proposal for a simplified grading scheme. Oral Oncol. 51, 71–76 (2015).
pubmed: 25456010
doi: 10.1016/j.oraloncology.2014.10.007
Tasoulas, J. et al. Impact of tumor site and adjuvant radiotherapy on survival of patients with adenoid cystic carcinoma: A SEER database analysis. Cancers 13, 589 (2021).
pubmed: 33546179
pmcid: 7913220
doi: 10.3390/cancers13040589
Lloyd, S. et al. Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy. Am. J. Clin. Oncol. 34, 76–81 (2011).
pubmed: 20177363
doi: 10.1097/COC.0b013e3181d26d45
Roh, J. L. et al. Carcinomas arising in the submandibular gland: High propensity for systemic failure. J. Surg. Oncol. 97, 533–537 (2008).
pubmed: 18286522
doi: 10.1002/jso.20993
Schwentner, I. et al. Distant metastasis of parotid gland tumors. Acta Otolaryngol. 126, 340–345 (2006).
pubmed: 16608783
doi: 10.1080/00016480500401035
Shin, D. Y. et al. Comparison of adenoid cystic carcinomas arising from the parotid gland vs. the submandibular gland: Focus on systemic metastasis and tumor-associated blood vessels. J. Oral Pathol. Med. 43, 441–447 (2014).
pubmed: 24456477
doi: 10.1111/jop.12155
Cornett, A. et al. Serial patient-derived orthotopic xenografting of adenoid cystic carcinomas recapitulates stable expression of phenotypic alterations and innervation. EBioMedicine 41, 175–184 (2019).
pubmed: 30765319
pmcid: 6442226
doi: 10.1016/j.ebiom.2019.02.011
Theocharis, S. et al. Salivary gland cancer in the era of immunotherapy: Can we exploit tumor microenvironment?. Expert Opin. Ther. Targets 24, 1047–1059 (2020).
pubmed: 32744127
doi: 10.1080/14728222.2020.1804863
Li, J. et al. Carcinoma-associated fibroblasts lead the invasion of salivary gland adenoid cystic carcinoma cells by creating an invasive track. PLoS ONE 11, e0150247 (2016).
pubmed: 26954362
pmcid: 4782997
doi: 10.1371/journal.pone.0150247
Kong, J. et al. Establishment and characterization of a carcinoma-associated fibroblast cell line derived from a human salivary gland adenoid cystic carcinoma. Cell Commun. Adhes. 24, 11–18 (2018).
pubmed: 29734861
doi: 10.1080/15419061.2018.1464000
Ruivo, C. F. et al. The biology of cancer exosomes: Insights and new perspectives. Cancer Res. 77, 6480–6488 (2017).
pubmed: 29162616
doi: 10.1158/0008-5472.CAN-17-0994
Xu, Z., Zheng, X. & Zheng, J. Tumor-derived exosomes educate fibroblasts to promote salivary adenoid cystic carcinoma metastasis via NGF-NTRK1 pathway. Oncol. Lett. https://doi.org/10.3892/ol.2019.10740 (2019).
doi: 10.3892/ol.2019.10740
pubmed: 32002036
pmcid: 6960395
Yang, W. W. et al. Epiregulin promotes lung metastasis of salivary adenoid cystic carcinoma. Theranostics 7, 3700–3714 (2017).
pubmed: 29109770
pmcid: 5667342
doi: 10.7150/thno.19712
Hou, J. et al. Tumor-derived exosomes enhance invasion and metastasis of salivary adenoid cystic carcinoma cells. J. Oral Pathol. Med. 47, 144–151 (2018).
pubmed: 29057556
doi: 10.1111/jop.12654
Yang, Z. et al. CCL2/CCR2 axis promotes the progression of salivary adenoid cystic carcinoma via recruiting and reprogramming the tumor-associated macrophages. Front. Oncol. 9, 231 (2019).
pubmed: 31024838
pmcid: 6465613
doi: 10.3389/fonc.2019.00231
Sridharan, V. et al. Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes. Cancer Immunol. Res. 4, 679–687 (2016).
pubmed: 27312343
doi: 10.1158/2326-6066.CIR-16-0031
Jeske, S. S. et al. Treatment-induced changes of lymphocyte subsets in patients with adenoid cystic carcinoma of the head and neck. Eur. Arch. Otorhinolaryngol. 276, 1465–1473 (2019).
pubmed: 30815724
doi: 10.1007/s00405-019-05363-2
Linxweiler, M. et al. The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-19-3758 (2020).
doi: 10.1158/1078-0432.CCR-19-3758
pubmed: 32060100
pmcid: 7918996
Brkic, F. F. et al. Pretreatment assessment of hematologic and inflammatory markers in adenoid cystic carcinoma: Neutrophil/lymphocyte ratio is associated with multiple recurrences. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 127, 408–416 (2019).
pubmed: 30745209
doi: 10.1016/j.oooo.2018.10.009
Sousa, L. G. et al. Spatial immunoprofiling of adenoid cystic carcinoma reveals B7–H4 is a therapeutic target for aggressive tumors. Clin. Cancer Res. 29, 3162–3171 (2023).
pubmed: 37256648
pmcid: 10526680
doi: 10.1158/1078-0432.CCR-23-0514
Ferrarotto, R. et al. Proteogenomic analysis of salivary adenoid cystic carcinomas defines molecular subtypes and identifies therapeutic targets. Clin. Cancer Res. 27, 852–864 (2021).
pubmed: 33172898
doi: 10.1158/1078-0432.CCR-20-1192
Rettig, E. M. et al. Whole-genome sequencing of salivary gland adenoid cystic carcinoma. Cancer Prev. Res. 9, 265–274 (2016).
doi: 10.1158/1940-6207.CAPR-15-0316
Oyelakin, A. et al. Transcriptomic and network analysis of minor salivary glands of patients with primary Sjögren’s syndrome. Front. Immunol. 11, 606268 (2020).
pubmed: 33488608
doi: 10.3389/fimmu.2020.606268
Saitou, M. et al. Functional specialization of human salivary glands and origins of proteins intrinsic to human saliva. Cell Rep. 33, 108402 (2020).
pubmed: 33207190
pmcid: 7703872
doi: 10.1016/j.celrep.2020.108402
Soneson, C., Love, M. & Robinson, M. Differential analyses for RNA-seq: Transcript-level estimates improve gene-level inferences [version 1; peer review: 2 approved]. F1000Research 4, 1521 (2015).
pubmed: 26925227
doi: 10.12688/f1000research.7563.1
Chen, Y., Lun, A. & Smyth, G. From reads to genes to pathways: Differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline [version 2; peer review: 5 approved]. F1000Research 5, 1438 (2016).
pubmed: 27508061
pmcid: 4934518
Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. 102, 15545–15550 (2005).
pubmed: 16199517
pmcid: 1239896
doi: 10.1073/pnas.0506580102
Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011).
pubmed: 21546393
pmcid: 3106198
doi: 10.1093/bioinformatics/btr260
Korotkevich, G. et al. Fast gene set enrichment analysis. bioRxiv 060012 (2021).
Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021
pmcid: 4707969
doi: 10.1016/j.cels.2015.12.004
Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517
pmcid: 1239896
doi: 10.1073/pnas.0506580102
Luca, B. A. et al. Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell 184, 5482-5496.e28 (2021).
pubmed: 34597583
pmcid: 8526411
doi: 10.1016/j.cell.2021.09.014
Hadley, W. Ggplot2 (Springer Science+Business Media, LLC, 2016).
Ram, K. & Wickham, H. wesanderson: a Wes Anderson palette generator. R package version 03 2018, Vol. 6 (2018).
Neuwirth, E. RColorBrewer: ColorBrewer palettes. R package version 1.1-2 (2014).
Kolde, R. Pheatmap: pretty heatmaps. R package version 2012, Vol. 1, 726.
Weinberg, F., Ramnath, N. & Nagrath, D. Reactive oxygen species in the tumor microenvironment: An overview. Cancers 11, 1191 (2019).
pubmed: 31426364
pmcid: 6721577
doi: 10.3390/cancers11081191
Kumar, R., Prasad, H. K. & Kumar, M. The double-edged sword role of ROS in cancer. In Handbook of Oxidative Stress in Cancer: Mechanistic Aspects (eds Chakraborti, S. et al.) 1–17 (Springer Singapore, 2020).
Rojo de la Vega, M., Chapman, E. & Zhang, D. D. NRF2 and the hallmarks of cancer. Cancer Cell 34, 21–43 (2018).
pubmed: 29731393
doi: 10.1016/j.ccell.2018.03.022
Morris, G. et al. Redox regulation of the immune response. Cell Mol. Immunol. 19, 1079–1101 (2022).
pubmed: 36056148
pmcid: 9508259
doi: 10.1038/s41423-022-00902-0
O’Connell, F. P., Pinkus, J. L. & Pinkus, G. S. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am. J. Clin. Pathol. 121, 254–263 (2004).
pubmed: 14983940
doi: 10.1309/617DWB5GNFWXHW4L
Ross, J. S. et al. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. Ann. Oncol. 28, 2539–2546 (2017).
pubmed: 28961851
pmcid: 5834110
doi: 10.1093/annonc/mdx399
Rodriguez, C. P. et al. A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clin. Cancer Res. 26, 837–845 (2020).
pubmed: 31796519
doi: 10.1158/1078-0432.CCR-19-2214
Even, C. et al. Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. Eur. J. Cancer 171, 259–268 (2022).
pubmed: 35777186
doi: 10.1016/j.ejca.2022.05.007
Cohen, R. B. et al. Pembrolizumab for the treatment of advanced salivary gland carcinoma: Findings of the phase 1b KEYNOTE-028 study. Am. J. Clin. Oncol. 41, 1083–1088 (2018).
pubmed: 29462123
pmcid: 6211783
doi: 10.1097/COC.0000000000000429
Patel, M. et al. BTCRC-HN17-111, A phase 2 trial of ADT (goserelin) in combination with pembrolizumab for patients with advanced salivary gland tumors expressing androgen receptor (AR). J. Clin. Oncol. 40, e18091 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.e18091
Fayette, J. et al. NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group. J. Clin. Oncol. 37, 6083 (2019).
doi: 10.1200/JCO.2019.37.15_suppl.6083
Tchekmedyian, V. et al. A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). J. Clin. Oncol. 37, 6084 (2019).
doi: 10.1200/JCO.2019.37.15_suppl.6084
Burman, B. et al. A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic salivary gland cancers (R/M SGCs). J. Clin. Oncol. 39, 6002 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.6002
Patel, S. P. et al. A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. Cancer 127, 3194–3201 (2021).
pubmed: 33882143
doi: 10.1002/cncr.33591
Mahmood, U. et al. A randomized phase 2 study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 109, 134–144 (2021).
pubmed: 32781104
doi: 10.1016/j.ijrobp.2020.08.018
Johnson, D. E. et al. Head and neck squamous cell carcinoma. Nat. Rev. Dis. Primers 6, 92 (2020).
pubmed: 33243986
pmcid: 7944998
doi: 10.1038/s41572-020-00224-3
Artinyan, A. et al. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB 10, 371–376 (2008).
pubmed: 18982154
pmcid: 2575681
doi: 10.1080/13651820802291233
Howard, M. D. et al. Anatomic location of primary melanoma: Survival differences and sun exposure. J. Am. Acad. Dermatol. 81, 500–509 (2019).
pubmed: 31009667
doi: 10.1016/j.jaad.2019.04.034
Petrelli, F. et al. Prognostic survival associated with left-sided vs right-sided colon cancer: A systematic review and meta-analysis. JAMA Oncol. 3, 211–219 (2017).
pubmed: 27787550
doi: 10.1001/jamaoncol.2016.4227
Weiss, J. M. et al. Anatomic position determines oncogenic specificity in melanoma. Nature 604, 354–361 (2022).
pubmed: 35355015
pmcid: 9355078
doi: 10.1038/s41586-022-04584-6
Nascimento, A. G. et al. Adenoid cystic carcinoma of salivary glands. A study of 61 cases with clinicopathologic correlation. Cancer 57, 312–319 (1986).
pubmed: 3002581
doi: 10.1002/1097-0142(19860115)57:2<312::AID-CNCR2820570220>3.0.CO;2-A
Kotsafti, A. et al. Reactive oxygen species and antitumor immunity-from surveillance to evasion. Cancers 12, 1748 (2020).
pubmed: 32630174
pmcid: 7409327
doi: 10.3390/cancers12071748
Saddawi-Konefka, R. et al. Tumor-expressed IL-17D recruits NK cells to reject tumors. Oncoimmunology 3, e954853 (2014).
pubmed: 25964859
doi: 10.4161/21624011.2014.954853
O’Sullivan, T. et al. Interleukin-17D mediates tumor rejection through recruitment of natural killer cells. Cell Rep. 7, 989–998 (2014).
pubmed: 24794441
pmcid: 4084720
doi: 10.1016/j.celrep.2014.03.073
Renken, S. et al. Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress. J. Immunother. Cancer 10, e004458 (2022).
pubmed: 35738800
pmcid: 9226989
doi: 10.1136/jitc-2021-004458
Poznanski, S. M. et al. Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment. Cell Metab. 33(1205–20), e5 (2021).
Ge, X. Y. et al. Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83. PLoS ONE 9, e101207 (2014).
pubmed: 24963720
pmcid: 4071064
doi: 10.1371/journal.pone.0101207
Sahara, S., Herzog, A. E. & Nor, J. E. Systemic therapies for salivary gland adenoid cystic carcinoma. Am. J. Cancer Res. 11, 4092–4110 (2021).
pubmed: 34659878
pmcid: 8493384
Lee, R. H. et al. Approaches to the management of metastatic adenoid cystic carcinoma. Cancers 14, 5698 (2022).
pubmed: 36428790
pmcid: 9688467
doi: 10.3390/cancers14225698
Vasaikar, S. V. et al. EMTome: A resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures. Br. J. Cancer 124, 259–269 (2021).
pubmed: 33299129
doi: 10.1038/s41416-020-01178-9
Wang, G. et al. The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response. npj Precis. Oncol. 5, 56 (2021).
pubmed: 34158591
pmcid: 8219790
doi: 10.1038/s41698-021-00200-4